Glucagon-Like Peptide-1 receptor agonists, dual GIP/GLP-1 receptor agonist tirzepatide and suicidal ideation and behavior: a systematic review of clinical studies and pharmacovigilance reports
Reductions in body weight were significantly greater with the LY3298176 1.5 mg, 4.5 mg and 10 mg doses versus placebo in MAD HS (LSM difference [95% CI]: -1.75 kg [-3.38, -0.12], -5.09 kg [-6.72, -3.46] and -4.61 kg [-6.21, -3.01], respectively) and doses of 10 mg and 15 mg had a relevant effect in T2DM patients (LSM difference [95% CI]: -2.62 kg [-3.79, -1.45] and -2.07 kg [-3.25, -0.88], respectively
3 Institute of Experimental Medicine Hungarian Academy of Sciences, Budapest, Hungary
In addition, all participants received cognitive behavioral therapy and frequent clinical contact, which may not reflect usual care
Wee CC, Mukamal KJ, Huskey KW, Davis RB, Colten ME, Bolcic-Jankovic D, et al
Nutrition: Focus on high-protein foods to help maintain muscle mass while you lose fat